文献速递临床试验与 GCP流行病学与生物统计

性传播感染筛查预防不良出生和新生儿结局:一项随机对照混合有效性试验的研究方案

Sexually transmitted infection screening to prevent adverse birth and newborn outcomes: study protocol for a randomized-controlled hybrid-effectiveness trial.
PubMed 文献 · Trials · 2022-05-24

该研究为三臂(1:1:1)1型混合有效性-实施随机对照试验,计划在南非东开普省Buffalo City Metro District的产前门诊招募2500名首次产检孕妇。干预组接受GeneXpert®即时检测淋病奈瑟菌、沙眼衣原体和阴道毛滴虫并当日治疗,对照组接受症状管理(标准治疗)。主要结局为不良出生结局频率和干预组与标准治疗相比的性传播感染患病率变化,并评估成本效果。

要点

  • 南非孕妇性传播感染患病率高且多无症状,标准症状管理导致多数感染未被发现和治疗。
  • 该试验为三臂随机对照设计,比较即时分子检测筛查与症状管理对不良出生结局的影响。
  • 研究将评估不同筛查策略的成本效果,为世界卫生组织(WHO)指南更新提供证据。

核心结论

  • 该试验旨在确定最佳、成本有效的筛查策略以降低孕期性传播感染负担和减少不良出生结局。
  • 证明诊断筛查和治疗与症状管理相比对出生结局的影响,将为WHO孕期性传播感染症状管理指南的修改提供关键证据。

研究设计与样本

  • 三臂(1:1:1)1型混合有效性-实施随机对照试验(RCT)。
  • 计划在南非东开普省Buffalo City Metro District参与卫生机构招募2500名当前妊娠首次产前保健(ANC)就诊的孕妇。
  • 参与者随机分配至第1臂、第2臂(干预)或第3臂(标准治疗)。
  • 第1臂和第2臂接受GeneXpert®即时诊断检测淋病奈瑟菌、沙眼衣原体和阴道毛滴虫,并对检测到的感染当日治疗。
  • 第1臂额外在治疗后3周接受治愈检测,第2臂在妊娠30-34周接受重复检测;第3臂接受症状管理(标准治疗)。

主要发现

  • 主要结局包括:(1)研究各组不良出生结局频率,定义为低出生体重和早产的综合指标;(2)干预组基线与出生结局之间性传播感染患病率的变化,并与标准治疗比较。
  • 将计算不同筛查策略相对于标准治疗的估计成本和比较成本,以及管理不良出生结局的成本。
  • 成本效果将按每种性传播感染和避免的残疾调整生命年评估。

关键数值与推荐

  • 招募2500名孕妇。
  • 随机分组比例1:1:1。
  • 第1臂治愈检测在治疗后3周。
  • 第2臂重复检测在妊娠30-34周。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sexually transmitted infections (STIs) during pregnancy are associated with adverse birth outcomes, including preterm birth, low birth weight, perinatal death, and congenital infections such as increased mother-to-child HIV transmission. Prevalence of STIs among pregnant women in South Africa remains high, with most women being asymptomatic for their infection(s). Unfortunately, most STIs remain undetected and untreated due to standard practice syndromic management in accordance with World Health Organization (WHO) guidelines. Although lab-based and point-of-care molecular tests are available, optimal screening strategies during pregnancy, their health impact, and cost-effectiveness are unknown. METHODS: We will implement a 3-arm (1:1:1) type-1 hybrid effectiveness-implementation randomized-controlled trial (RCT). We will enroll 2500 pregnant women attending their first antenatal care (ANC) visit for their current pregnancy at participating health facilities in Buffalo City Metro District, Eastern Cape Province, South Africa. Participants allocated to arms 1 and 2 (intervention) will receive GeneXpert® point-of-care diagnostic testing for Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis, with same-day treatment for detected infection(s). Arm 1 will additionally receive a test-of-cure 3 weeks post-treatment, while Arm 2 will receive a repeat test at 30-34 weeks' gestation. Those allocated to Arm 3 will receive syndromic management (standard-of-care). The RE-AIM framework will be used to guide collection of implementation indicators to inform potential future scale up. Primary outcome measures include (1) frequency of adverse birth outcomes among study arms, defined by a composite measure of low birth weight and pre-term delivery, and (2) change in STI prevalence between baseline and birth outcome among intervention arms and compared to standard-of-care. Estimates and comparative costs of the different screening strategies relative to standard-of-care and the costs of managing adverse birth outcomes will be calculated. Cost-effectiveness will be assessed per STI and disability-adjusted life year averted. DISCUSSION: This trial is the first RCT designed to identify optimal, cost-effective screening strategies that decrease the burden of STIs during pregnancy and reduce adverse birth outcomes. Demonstrating the impact of diagnostic screening and treatment, compared to syndromic management, on birth outcomes will provide critical evidence to inform changes to WHO guidelines for syndromic management of STIs during pregnancy. TRIAL REGISTRATION: ClinicalTrials.gov NCT04446611 . Registered on 25 June 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Medina-Marino A, Cleary S, Muzny CA, et al. Sexually transmitted infection screening to prevent adverse birth and newborn outcomes: study protocol for a randomized-controlled hybrid-effectiveness trial. Trials. 2022. PMID: 35610666. doi:10.1186/s13063-022-06400-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。